{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T19:07:44Z","timestamp":1790276864526,"version":"4.1.0"},"reference-count":83,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["journal-of-hepatology.eu","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.jhep.2015.09.008","type":"journal-article","created":{"date-parts":[[2015,10,21]],"date-time":"2015-10-21T05:33:51Z","timestamp":1445405631000},"page":"736-745","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Clinical implications of basic research in hepatocellular carcinoma"],"prefix":"10.1016","volume":"64","author":[{"given":"Renumathy","family":"Dhanasekaran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhakar K.","family":"Venkatesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Torbenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis R.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2015.09.008_b0005","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jhep.2015.09.008_b0010","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.09.008_b0015","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2015.09.008_b0020","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.1200\/JCO.2012.45.8372","article-title":"Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial","volume":"31","author":"Cheng","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2015.09.008_b0025","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1200\/JCO.2012.47.3009","article-title":"Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study","volume":"31","author":"Llovet","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2015.09.008_b0030","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1001\/jama.2014.7189","article-title":"Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial","volume":"312","author":"Zhu","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2015.09.008_b0035","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/modpathol.2015.4","article-title":"DNAJB1-PRKACA is specific for fibrolamellar carcinoma","volume":"28","author":"Graham","year":"2015","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jhep.2015.09.008_b0040","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.ejca.2011.12.021","article-title":"EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma","volume":"48","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jhep.2015.09.008_b0045","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.24199","article-title":"Management of hepatocellular carcinoma: an update","volume":"53","author":"Bruix","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.09.008_b0050","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1002\/lt.22374","article-title":"Is tumor biopsy necessary?","volume":"17","author":"M\u00fcllhaupt","year":"2011","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2015.09.008_b0055","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/hep.21966","article-title":"Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma","volume":"47","author":"Forner","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.09.008_b0060","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/ajg.2009.654","article-title":"The impact of vascular and nonvascular findings on the noninvasive diagnosis of small hepatocellular carcinoma based on the EASL and AASLD criteria","volume":"105","author":"Leoni","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2015.09.008_b0065","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1148\/radiol.14140690","article-title":"Hepatocellular Carcinoma: Diagnostic Performance of Multidetector CT and MR Imaging\u2014A Systematic Review and Meta-Analysis","volume":"275","author":"Lee","year":"2015","journal-title":"Radiology"},{"key":"10.1016\/j.jhep.2015.09.008_b0070","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.2214\/AJR.05.1226","article-title":"Quadruple-phase MDCT of the liver in patients with suspected hepatocellular carcinoma: effect of contrast material flow rate","volume":"186","author":"Schima","year":"2006","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.jhep.2015.09.008_b0075","doi-asserted-by":"crossref","first-page":"498","DOI":"10.2214\/AJR.13.12399","article-title":"Consensus statements from a multidisciplinary expert panel on the utilization and application of a liver-specific MRI contrast agent (gadoxetic acid)","volume":"204","author":"Jhaveri","year":"2015","journal-title":"Am J Roentgenol"},{"key":"10.1016\/j.jhep.2015.09.008_b0080","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/s00261-011-9692-2","article-title":"Hepatocellular nodules in liver cirrhosis: MR evaluation","volume":"36","author":"Lee","year":"2011","journal-title":"Abdom Imaging"},{"key":"10.1016\/j.jhep.2015.09.008_b0085","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1148\/radiol.13120775","article-title":"Hepatocellular carcinoma: imaging patterns on gadoxetic acid-enhanced MR Images and their value as an imaging biomarker","volume":"267","author":"Choi","year":"2013","journal-title":"Radiology"},{"key":"10.1016\/j.jhep.2015.09.008_b0090","first-page":"145","article-title":"The role of contrast enhanced ultrasound (CEUS) in the assessment of liver nodules in patients with cirrhosis","volume":"12","author":"Danila","year":"2010","journal-title":"Med Ultrasonography"},{"key":"10.1016\/j.jhep.2015.09.008_b0095","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ultrasmedbio.2012.09.002","article-title":"Guidelines and good clinical practice recommendations for Contrast Enhanced Ultrasound (CEUS) in the liver \u2013 update 2012: A WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS","volume":"39","author":"Claudon","year":"2013","journal-title":"Ultrasound Med Biol"},{"key":"10.1016\/j.jhep.2015.09.008_b0100","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.2214\/AJR.10.4310","article-title":"Correlation between contrast-enhanced intraoperative ultrasound using Sonazoid and histologic grade of resected hepatocellular carcinoma","volume":"196","author":"Arita","year":"2011","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.jhep.2015.09.008_b0105","doi-asserted-by":"crossref","first-page":"625","DOI":"10.7863\/jum.2011.30.5.625","article-title":"Evaluation of hepatocellular carcinoma by contrast-enhanced sonography: correlation with pathologic differentiation","volume":"30","author":"Xu","year":"2011","journal-title":"J Ultrasound Med"},{"key":"10.1016\/j.jhep.2015.09.008_b0110","doi-asserted-by":"crossref","first-page":"400","DOI":"10.2214\/ajr.185.2.01850400","article-title":"Needle tract implantation after sonographically guided percutaneous biopsy of hepatocellular carcinoma: evaluation of doubling time, frequency, and features on CT","volume":"185","author":"Chang","year":"2005","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.jhep.2015.09.008_b0115","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1136\/gut.2008.149062","article-title":"Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis","volume":"57","author":"Silva","year":"2008","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2015.09.008_b0120","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/hep.27545","article-title":"Liver cancer biopsy \u2013 Back to the future?!","volume":"61","author":"Torbenson","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.09.008_b0125","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/hep.27563","article-title":"Biopsy for liver cancer: how to balance research needs with evidence-based clinical practice","volume":"61","author":"Sherman","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.09.008_b0130","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10549-012-2247-6","article-title":"Impact of biomarkers on clinical trial risk in breast cancer","volume":"136","author":"Parker","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jhep.2015.09.008_b0135","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/JTO.0000000000000075","article-title":"Biomarkers and receptor targeted therapies reduce clinical trial risk in non-small-cell lung cancer","volume":"9","author":"Falconi","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jhep.2015.09.008_b0140","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1470-2045(12)70490-4","article-title":"Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study","volume":"14","author":"Santoro","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2015.09.008_b0145","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/j.transproceed.2009.03.054","article-title":"Validation of the BCLC prognostic system in surgical hepatocellular cancer patients","volume":"41","author":"Vitale","year":"2009","journal-title":"Transplant Proc"},{"key":"10.1016\/j.jhep.2015.09.008_b0150","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.jhep.2005.12.015","article-title":"Prospective validation of the Barcelona Clinic Liver Cancer staging system","volume":"44","author":"Cillo","year":"2006","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.09.008_b0155","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1111\/j.1478-3231.2012.02811.x","article-title":"Applicability of BCLC stage for prognostic stratification in comparison with other staging systems: single centre experience from long-term clinical outcomes of 1717 treatment-na\u00efve patients with hepatocellular carcinoma","volume":"32","author":"Kim","year":"2012","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2015.09.008_b0160","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/hep.20636","article-title":"Prognosis of hepatocellular carcinoma: Comparison of 7 staging systems in an American cohort","volume":"41","author":"Marrero","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.09.008_b0165","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/hep.20375","article-title":"Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling","volume":"40","author":"Lee","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.09.008_b0170","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/nm1377","article-title":"A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells","volume":"12","author":"Lee","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2015.09.008_b0175","doi-asserted-by":"crossref","first-page":"7385","DOI":"10.1158\/0008-5472.CAN-09-1089","article-title":"Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma","volume":"69","author":"Hoshida","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.jhep.2015.09.008_b0180","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1053\/gast.2001.24798","article-title":"Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis","volume":"120","author":"Laurent-Puig","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.09.008_b0185","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1172\/JCI27236","article-title":"Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype","volume":"116","author":"Kaposi-Novak","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jhep.2015.09.008_b0190","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1002\/hep.22283","article-title":"Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer","volume":"47","author":"Coulouarn","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.09.008_b0195","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.1158\/1078-0432.CCR-09-3274","article-title":"A seven-gene set associated with chronic hypoxia of prognostic importance in hepatocellular carcinoma","volume":"16","author":"van Malenstein","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhep.2015.09.008_b0200","doi-asserted-by":"crossref","first-page":"6120","DOI":"10.1038\/ncomms7120","article-title":"Whole-genome mutational landscape of liver cancers displaying biliary phenotype reveals hepatitis impact and molecular diversity","volume":"6","author":"Fujimoto","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhep.2015.09.008_b0205","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1053\/j.gastro.2013.03.051","article-title":"A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection","volume":"145","author":"Nault","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.09.008_b0210","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1007\/s00268-010-0598-x","article-title":"Comparing hepatic resection and transarterial chemoembolization for Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma: change for treatment of choice?","volume":"34","author":"Lin","year":"2010","journal-title":"World J Surg"},{"key":"10.1016\/j.jhep.2015.09.008_b0215","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jhep.2014.03.012","article-title":"Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan criteria: a RCT","volume":"61","author":"Yin","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.09.008_b0220","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1053\/jhep.2001.24563","article-title":"Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival","volume":"33","author":"Yao","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.09.008_b0225","first-page":"348","article-title":"Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions","volume":"32","author":"Bolondi","year":"2012","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2015.09.008_b0230","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1002\/hep.25956","article-title":"FGF3\/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma","volume":"57","author":"Arao","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.09.008_b0235","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1158\/2159-8290.CD-13-0782","article-title":"Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment","volume":"4","author":"Horwitz","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jhep.2015.09.008_b0240","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1002\/ijc.28772","article-title":"VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study","volume":"135","author":"Scartozzi","year":"2014","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jhep.2015.09.008_b0245","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1111\/liv.12778","article-title":"Expression of pERK and VEGFR-2 in advanced hepatocellular carcinoma and resistance to sorafenib treatment","volume":"35","author":"Negri","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2015.09.008_b0250","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1002\/hep.27739","article-title":"Making sorafenib irresistible. In vivo screening for mechanisms of therapy resistance in hepatocellular carcinoma hits on Mapk14","volume":"61","author":"Avila","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.09.008_b0255","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1200\/JCO.2013.54.3298","article-title":"Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial","volume":"33","author":"Cainap","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2015.09.008_b0260","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1200\/JCO.2008.18.3301","article-title":"Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma","volume":"27","author":"Thomas","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2015.09.008_b0265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/annonc\/mdu438.16","article-title":"LBA16 \u2013 Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC) following first-line therapy with sorafenib: Results from the randomized phase III REACH study","volume":"25","author":"Zhu","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2015.09.008_b0270","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/341636","article-title":"Targeting the HGF-cMET axis in hepatocellular carcinoma","volume":"2013","author":"Venepalli","year":"2013","journal-title":"Int J Hepatol"},{"key":"10.1016\/j.jhep.2015.09.008_b0275","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1172\/JCI27236","article-title":"Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype","volume":"116","author":"Kaposi-Novak","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jhep.2015.09.008_b0280","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1158\/1078-0432.CCR-11-2175","article-title":"Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma","volume":"18","author":"Llovet","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhep.2015.09.008_b0285","doi-asserted-by":"crossref","unstructured":"Verslype C, Cohn AL, Kelley RK, Yang TS, Su WC, Ramies DA, et al. Activity of cabozantinib (XL184) in hepatocellular carcinoma: results from a phase II randomized discontinuation trial (RDT). ASCO Meeting Abstracts 2012;30:4007.","DOI":"10.1200\/jco.2012.30.15_suppl.4007"},{"key":"10.1016\/j.jhep.2015.09.008_b0290","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.jhep.2015.02.038","article-title":"The yin and yang of evasion and immune activation in HCC","volume":"62","author":"Makarova-Rusher","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.09.008_b0295","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1159\/000343837","article-title":"Immunotherapeutic approaches to hepatocellular carcinoma treatment","volume":"1","author":"Miamen","year":"2012","journal-title":"Liver Cancer"},{"key":"10.1016\/j.jhep.2015.09.008_b0300","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1158\/0008-5472.CAN-04-3232","article-title":"Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma","volume":"65","author":"Ormandy","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.jhep.2015.09.008_b0305","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1053\/j.gastro.2007.03.102","article-title":"Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients","volume":"132","author":"Fu","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.09.008_b0310","doi-asserted-by":"crossref","first-page":"8067","DOI":"10.1158\/0008-5472.CAN-09-0901","article-title":"Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7\u2013H1\/programmed death-1 interactions","volume":"69","author":"Wu","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.jhep.2015.09.008_b0315","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1158\/0008-5472.CAN-12-3381","article-title":"Higher frequencies of GARP(+)CTLA-4(+)Foxp3(+) T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-cell functionality","volume":"73","author":"Kalathil","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.jhep.2015.09.008_b0320","doi-asserted-by":"crossref","first-page":"e32493","DOI":"10.1371\/journal.pone.0032493","article-title":"Immunological and molecular correlates of disease recurrence after liver resection for hepatocellular carcinoma","volume":"7","author":"Cariani","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2015.09.008_b0325","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1002\/hep.24149","article-title":"Comparative analysis of various tumor-associated antigen-specific t-cell responses in patients with hepatocellular carcinoma","volume":"53","author":"Mizukoshi","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.09.008_b0330","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00535-009-0155-2","article-title":"Strong CD8(+) T-cell responses against tumor-associated antigens prolong the recurrence-free interval after tumor treatment in patients with hepatocellular carcinoma","volume":"45","author":"Hiroishi","year":"2010","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jhep.2015.09.008_b0335","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1158\/1078-0432.CCR-05-2856","article-title":"A phase I\/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides","volume":"12","author":"Butterfield","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhep.2015.09.008_b0340","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/1471-2407-10-209","article-title":"A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma","volume":"10","author":"Greten","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jhep.2015.09.008_b0345","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1158\/1078-0432.CCR-11-3044","article-title":"Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival","volume":"18","author":"Sawada","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhep.2015.09.008_b0350","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1002\/hep.26893","article-title":"Epitope-optimized alpha-fetoprotein genetic vaccines prevent carcinogen-induced murine autochthonous hepatocellular carcinoma","volume":"59","author":"Hong","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.09.008_b0355","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.clinthera.2015.02.018","article-title":"The next immune-checkpoint inhibitors: PD-1\/PD-L1 blockade in melanoma","volume":"37","author":"Mahoney","year":"2015","journal-title":"Clin Ther"},{"key":"10.1016\/j.jhep.2015.09.008_b0360","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.2217\/fon.15.52","article-title":"Nivolumab: targeting PD-1 to bolster antitumor immunity","volume":"11","author":"Brahmer","year":"2015","journal-title":"Future Oncol"},{"key":"10.1016\/j.jhep.2015.09.008_b0365","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jhep.2013.02.022","article-title":"A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C","volume":"59","author":"Sangro","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.09.008_b0370","doi-asserted-by":"crossref","unstructured":"El-Khoueiry AB, Melero I, Crocenzi TS, et al. Phase I\/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040. J Clin Oncol 2015 (suppl; abstr LBA101).","DOI":"10.1200\/jco.2015.33.18_suppl.lba101"},{"key":"10.1016\/j.jhep.2015.09.008_b0375","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1038\/ncomms3218","article-title":"High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions","volume":"4","author":"Nault","year":"2013","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhep.2015.09.008_b0380","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/annonc\/mdu550","article-title":"A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer","volume":"26","author":"Chiappori","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2015.09.008_b0385","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s10549-015-3270-1","article-title":"The telomerase inhibitor imetelstat alone, and in combination with trastuzumab, decreases the cancer stem cell population and self-renewal of HER2+ breast cancer cells","volume":"149","author":"Koziel","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jhep.2015.09.008_b0390","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/ng.2256","article-title":"Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma","volume":"44","author":"Guichard","year":"2012","journal-title":"Nat Genet"},{"key":"10.1016\/j.jhep.2015.09.008_b0395","doi-asserted-by":"crossref","first-page":"6536","DOI":"10.1038\/ncomms7536","article-title":"Immunotoxin targeting glypican-3 regresses liver cancer via dual inhibition of Wnt signalling and protein synthesis","volume":"6","author":"Gao","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhep.2015.09.008_b0400","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1158\/0008-5472.CAN-14-0243","article-title":"Transforming growth factor-beta as a therapeutic target in hepatocellular carcinoma","volume":"74","author":"Giannelli","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.jhep.2015.09.008_b0405","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1002\/hep.23118","article-title":"Inhibition of transforming growth factor \u03b2 receptor I kinase blocks hepatocellular carcinoma growth through neo-angiogenesis regulation","volume":"50","author":"Mazzocca","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.09.008_b0410","doi-asserted-by":"crossref","unstructured":"Faivre S SA, Kelley RK, et al. A Phase 2 study of novel transforming growth factor-beta (TGF-\u03b2) receptor 1 kinase inhibitor, LY2157299 monohydrate in patients with advanced hepatocellular carcinoma (HCC). In: Presented at: 2014 Gastrointestinal Cancers Symposium; January 16-18, 2014; San Francisco, CA. \u2013 See more at: http:\/\/www.onclive.com\/conference-coverage\/gcs-2014\/Novel-Targeted-Agent-Leads-to-Survival-Benefit-in-HCC \u2013 sthash.WYz42iCN.dpuf.","DOI":"10.1200\/jco.2014.32.3_suppl.lba173"},{"key":"10.1016\/j.jhep.2015.09.008_b0415","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1053\/j.seminoncol.2014.01.001","article-title":"Management of sorafenib-related adverse events: a clinician\u2019s perspective","volume":"41","author":"Brose","year":"2014","journal-title":"Semin Oncol"}],"updated-by":[{"DOI":"10.1016\/j.jhep.2016.02.036","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000}}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827815006261?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827815006261?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T01:16:34Z","timestamp":1599700594000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827815006261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":83,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["S0168827815006261"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2015.09.008","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.jhep.2016.02.036","asserted-by":"object"}]},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical implications of basic research in hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2015.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}